8-K: Carlsmed Reports Soaring 2025 Revenue, Strong Growth

Carlsmed, a medical technology company, announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and gross margin expansion.

Summary

• Fourth quarter 2025 revenue increased 61.2% year-over-year to $15.2 million.
• Full year 2025 revenue grew 86% year-over-year to $50.5 million.
• Gross margin expanded to 76.5% in Q4 2025 and 75.3% for the full year 2025.
• Net loss increased to ($8.6) million in Q4 2025 and ($29.6) million for the full year 2025 due to increased operating expenses.
• Cash and cash equivalents, restricted cash, and short-term investments totaled $109.9 million as of December 31, 2025.
• Launched aprevo cervical system and myaprevo ecosystem for browser and mobile integration.
• Published 2-year aprevo lumbar outcome data showing a 74% reduction in revision rates at two years for aprevo lumbar patients versus non-aprevo patients.
• Performed first in human aprevo bi-lateral posterior fusion and personalized corra cervical plating procedures in February 2026.
• Lead times were reduced to within six business days.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report for a growth company, demonstrating excellent top-line expansion, margin improvement, and significant product development, despite increased losses typical of a scaling medical technology firm.

Positives

• Strong revenue growth: 61.2% year-over-year in Q4 2025 ($15.2 million) and 86% year-over-year for full year 2025 ($50.5 million).
• Gross margin expansion: 76.5% in Q4 2025 (up from 74.7% in Q4 2024) and 75.3% for full year 2025 (up from 73.8% in 2024).
• Positive clinical outcomes: 2-year aprevo lumbar data showed a 74% reduction in revision rates for aprevo lumbar patients.
• Product innovation and expansion: Launched aprevo cervical system and myaprevo ecosystem.
• Successful first-in-human procedures for aprevo bi-lateral posterior fusion and personalized corra cervical plating in February 2026.
• Operational efficiency improvement: Lead times reduced to within six business days.
• Strong cash position: $109.9 million in cash, restricted cash, and short-term investments as of December 31, 2025.
• Positive future outlook: 2026 revenue expected to be $70 million to $75 million, representing 44% growth at the midpoint over 2025.

Negatives

• Increased net loss: Q4 2025 net loss of ($8.6) million (compared to ($4.7) million in Q4 2024) and full year 2025 net loss of ($29.6) million (compared to ($24.3) million in 2024).
• Increased Adjusted EBITDA loss: Q4 2025 Adjusted EBITDA of ($8.4) million (compared to ($4.6) million in Q4 2024) and full year 2025 Adjusted EBITDA of ($28.4) million (compared to ($23.7) million in 2024).
• Significant increase in operating expenses: Total operating expenses rose to $20.9 million in Q4 2025 (from $11.7 million) and $68.6 million for full year 2025 (from $44.2 million), driven by R&D, Sales & Marketing, and General & Administrative expenses.

Future Outlook

Carlsmed anticipates 2026 revenue to be in the range of $70 million to $75 million, which would represent a 44% growth at the midpoint compared to 2025, indicating continued strong expansion.

Management Comments

• "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture of patient-centric innovation."
• "With recent published data from a patient-matched cohort showing a 74% reduction in revision rates at two years for aprevo lumbar patients versus non-aprevo patients, we continue to advance our mission of improved outcomes and reduced cost of healthcare with a highly differentiated approach."

Industry Context

StockSavvy.ai notes that Carlsmed's strong revenue growth and gross margin expansion, coupled with significant product development and positive clinical data for its AI-enabled personalized spine surgery solutions, position it as a rapidly emerging player in the competitive medical technology sector. The focus on patient-matched outcomes and reduced revision rates aligns with broader industry trends emphasizing value-based care and personalized medicine.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, expanding gross margins, and positive product development, though current losses persist. The significant increase in common shares issued suggests dilution for existing shareholders if they did not participate in the capital raise, but also indicates strong investor confidence and a strengthened balance sheet.
• Customers (Surgeons/Hospitals): Benefit from innovative, personalized spine surgery solutions (aprevo, corra) with demonstrated improved patient outcomes (74% reduction in revision rates) and reduced lead times.
• Patients: Direct benefit from improved surgical outcomes and reduced revision rates through personalized AI-enabled solutions.
• Employees: Continued growth and expansion likely create opportunities, but increased operating expenses suggest high investment in personnel.

Next Steps

• Carlsmed will host a conference call and concurrent webcast on February 25, 2026, at 4:30 pm Eastern Time to review the Q4 and full year 2025 performance.
• Continued execution on the 2026 financial outlook of $70 million to $75 million in revenue.
• Further development and commercialization of aprevo cervical system and myaprevo ecosystem.
• Ongoing clinical procedures for aprevo bi-lateral posterior fusion and personalized corra cervical plating.

Key Dates

Recommendation

Carlsmed's filing demonstrates exceptional revenue growth, expanding gross margins, and significant advancements in its product pipeline, including positive clinical data and new system launches. While net losses increased, this is characteristic of a high-growth medical technology company investing heavily in scaling operations and R&D. The strong cash position, likely bolstered by a recent capital raise, provides a solid foundation for future expansion. The positive 2026 revenue outlook further reinforces the company's strong growth trajectory and market potential, making it an attractive investment for growth-oriented portfolios.

Keywords

Carlsmed, CARL, Medical Technology, Spine Surgery, AI-enabled, Personalized Medicine, Financial Results, Revenue Growth, Gross Margin, Net Loss, Adjusted EBITDA, aprevo, cervical system, lumbar fusion, myaprevo, Q4 2025, Full Year 2025, 2026 Outlook